The FDA approvals of siponimod and cladribine for secondary progressive multiple sclerosis raise questions about the diagnostic criteria for multiple sclerosis phenotypes and their applicability to clinical trials. A simpler classification for the disease could be the answer.
|Original language||English (US)|
|Number of pages||2|
|Journal||Nature Reviews Neurology|
|State||Published - Aug 1 2019|
ASJC Scopus subject areas
- Clinical Neurology
- Cellular and Molecular Neuroscience